| galantamine hydrobromide / Generic mfg. |
NCT00338117: Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With Alzheimer's Disease |
|
|
| Completed | 3 | 554 | US | Galantamine hydrobromide | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Shire | Alzheimer's Disease, Dementia | | 05/97 | | |
NCT00253201: A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease |
|
|
| Completed | 3 | 636 | US | galantamine hydrobromide | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Alzheimer Disease, Dementia | | 10/97 | | |
NCT00253188: A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease |
|
|
| Completed | 3 | 653 | US | galantamine hydrobromide | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Alzheimer Disease, Dementia | | 12/98 | | |
NCT00253227: A Study of the Safety and Effectiveness of a Flexible Dose of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease |
|
|
| Completed | 3 | 387 | US | galantamine hydrobromide | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Alzheimer Disease, Dementia | | 12/98 | | |
NCT00309725: A Cardiac Safety Study of Galantamine in the Treatment of Alzheimer's Disease. |
|
|
| Completed | 3 | 139 | US | galantamine | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Alzheimer's Disease | | 10/99 | | |
NCT00261573: A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia |
|
|
| Completed | 3 | 593 | US | galantamine hydrobromide | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Alzheimer Disease, Vascular Dementia | | 12/00 | | |
| Completed | 3 | 241 | US | galantamine | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Alzheimer Disease | | 03/02 | | |
NCT00253214: Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation |
|
|
| Completed | 3 | 973 | US | galantamine hydrobromide | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Alzheimer Disease, Dementia | | 07/02 | | |
NCT00236574: A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment |
|
|
| Completed | 3 | 974 | US | Galantamine hydrobromide | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Dementia, Alzheimer Disease | | 11/03 | | |
NCT00236431: A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment |
|
|
| Completed | 3 | 1063 | US | Galantamine hydrobromide | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Dementia, Alzheimer Disease | | 12/03 | | |
NCT00301574: An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease. |
|
|
| Completed | 3 | 398 | Japan | galantamine | Janssen Pharmaceutical K.K. | Alzheimer Disease | | 02/04 | | |
NCT00240695: A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment |
|
|
| Completed | 3 | 724 | US | galantamine hydrobromide | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Cognition Disorder, Nervous System Diseases, Mental Disorders, Brain Diseases | | 05/04 | | |
NCT00645190: A Randomized, Double-blind, Flexible Dose, Multicenter Study to Evaluate the Effectiveness and Safety of Galantamine IR in Mild to Moderate Alzheimer's Disease |
|
|
| Completed | 3 | 215 | RoW | Galantamine HBr | Xian-Janssen Pharmaceutical Ltd. | Alzheimer Disease | | 02/05 | | |
NCT00216502: A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer's Disease |
|
|
| Completed | 3 | 254 | Europe | galantamine hydrobromide | Janssen-Cilag S.p.A. | Alzheimer Disease, Dementia, Mental Disorders, Brain Diseases | | 11/05 | | |
NCT00216593: Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study |
|
|
| Completed | 3 | 415 | Europe | galantamine hydrobromide | Janssen Pharmaceutica N.V., Belgium | Dementia, Alzheimer Disease | 09/07 | 03/08 | | |
NCT00814801: An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease |
|
|
| Completed | 3 | 580 | Japan | Placebo, Galantamine 16 mg/day, Galantamine 24 mg/day | Janssen Pharmaceutical K.K. | Alzheimer's Disease | 09/08 | 09/08 | | |
NCT00679627: A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease |
|
|
| Terminated | 3 | 2051 | Europe, RoW | Galantamine, Placebo | Janssen Research & Development, LLC | Alzheimer's Disease | 04/12 | 05/12 | | |
NCT02035982: Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease |
|
|
| Completed | 3 | 40 | Canada | Cholinesterase Inhibitor, Galantamine, Donepezil, Rivastigmine, Placebo | Sunnybrook Health Sciences Centre | Alzheimer's Disease, Dementia | 05/14 | 09/15 | | |
